|Day's Range||0.834 - 0.863|
|52 Week Range||0.810 - 1.530|
|PE Ratio (TTM)||13.45|
|Earnings Date||Jan 10, 2017 - Jan 16, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.51|
Acasti Pharma Inc. , today announced the correction of its stock option grant announcement made on June 14, 2017. It was previously stated that Acasti granted an aggregate of 1,021,500 stock options to ...
Acasti Pharma Inc. , today announced the grant of an aggregate of 1,021,500 stock options to its employees, executives and members of the Board of Directors under the Corporation's Stock Option Plan. Subject ...
Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of CaPre for the treatment of severe hypertriglyceridemia, today announced that the company ...